Table 1 Patient characteristics
Characteristic | Value or no. of patients (%) | ||
|---|---|---|---|
No LS (n = 75) | With LSa (n = 31) | ||
Age, years | |||
Median (range) | 37 (19–73) | 32.0 (18–61) | |
Sex | |||
Female | 40 (53) | 21 (68) | |
Male | 35 (47) | 10 (32) | |
Ethnicity | |||
Caucasian | 59 (78.6) | 25 (81) | |
African-American | 4 (5.4) | 2 (6) | |
Hispanic | 10 (13.4) | 4 (12) | |
Mid-eastern | 2 (2.6) | 0 | |
Histology | |||
Hodgkin lymphoma | 56 (75) | 26 (84) | |
Non-Hodgkin lymphoma | 19 (25) | 5 (16) | |
Disease stage | |||
I | 3 (4) | 3 (10) | |
II | 55 (73.5) | 24 (77) | |
III | 2 (3) | 2 (6.5) | |
IV | 4 (5) | 2 (6.5) | |
Recurrent | 3 (4) | ||
Refractory | 6 (8) | ||
Unknown | 2 (3) | ||
Radiation technique | |||
IMRT | 71 (95) | 29 (94) | |
IMRT & 3D AP/PA | 3 (4) | 1 (3) | |
Protons | 1 (1) | 1 (3) | |
RT dose, Gy | |||
Mean (range) | 32.9 (20–46) | 33.2 (30.6–46.6) | |
≤30.6 | 49 (65) | 22 (71) | |
>30.6 | 26 (35) | 9 (29) | |
30–36 | 10 (13) | 2 (6.5) | |
36–45 | 16 (22) | 7 (22.5) | |
Peripheral neuropathyb | |||
Yes | 35 (47) | 16 (52) | |
No | 39 (52) | 14 (45) | |
Unknown | 1 (1) | 1 (3) | |
Bleomycin toxicityb | |||
Yes | 62 (83) | 7 (23) | |
No | 3 (4) | 24 (77) | |
Decreased lung functionc | |||
Yes | 10 (13) | 11 (35) | |
No | 65 (87) | 20 (65) | |